



ANALYSIS OF THE USE OF ISAVUCONAZOLE IN CRITICALLY ILL PATIENTS WHEN THE USE OF VORICONAZOLE IS INDICATED

MARTÍNEZ-OREA G^{1,2}, GARCÍA-GONZÁLEZ C¹, FUENTES-HIDALGO F¹, RODRÍGUEZ-LUCENA FJ¹, DEVESA GARCIA C¹, CANO-CUENCA N¹.

¹Hospital Pharmacy – Hospital Vega Baja de Orihuela, 03314 Alicante, Spain

²Email: martinez_gabriel@gva.es




Background and Importance

Isavuconazole and **voriconazole** are antifungals with similar clinical efficacy in the treatment of invasive aspergillosis. However, its similar efficacy limits the use of isavuconazole in situations where voriconazole is contraindicated.

Aim and Objectives

To describe the proportion of isavuconazole prescriptions in which the use of voriconazole would not be contraindicated


Materials and Methods

-  Observational retrospective study
-  Patients treated with **Isavuconazole** in **2021**
-  % of patients who can be treated with voriconazole

Voriconazole is contraindicated:

- ✔ ClCr < 50 mL/min
- ✔ Severe hepatic insufficiency (Child-Pugh C)
- ✔ In combination with CYP450 substrates

Results



Conclusion

65% of patients treated with isavuconazole in our critical care unit did not meet the conditions for which it was included in the pharmacotherapeutic guide of the hospital. These results suggest the need for a specific PROA in critical patients or the multidisciplinary elaboration of a protocol for the use of antifungals